摘要
To the Editor:De-escalating the treatment of ductal carcinoma in situ(DCIS)of the breast has been investigated in recent years.A 5-year adjuvant endocrine therapy(AET)regimen is the recommended treatment for hormone receptor-positive DCIS.Selective estrogen receptor modulators(such as the commonly used tamoxifen and toremifene)and aromatase inhibitors(AIs)are the currently used AET drugs.However,long-term AET is accompanied by severe side effects such as menopausal symptoms,endometrial carcinoma,cardiovascular events,venous thromboembolic events,osteoporosis,and joint pain that can significantly reduce patients’quality of life.It was reported that only 50%of the patients completed the recommended 5-year AET mainly because of side effects,while higher adherence rates were observed with shorter-duration regimens.[1,2]Therefore,de-escalation of AET should be considered to reduce the side effects of AET and improve adherence.
基金
funded by grants from the 2023 Applied Basic research project of Liaoning province(No.2023JH2/101300048 to B.Chen)
2021 Science and Technology project of Shenyang(No.21-173-9-07 to G.Zhu).
